Urinary thromboxane and risk of cardiovascular events: role of aspirin
Graphical Abstract Graphical Abstract The ASCEND substudy: a summary of results of the observational association between U-TXM and clinical outcomes, and the randomized comparison of aspirin and placebo on U-TXM and clinical outcomes. Observational findings showed positive correlations between U-TXM...
Gespeichert in:
Veröffentlicht in: | European heart journal 2024-04, Vol.45 (15), p.1368-1370 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1370 |
---|---|
container_issue | 15 |
container_start_page | 1368 |
container_title | European heart journal |
container_volume | 45 |
creator | Eikelboom, John W Kruger, Paul C |
description | Graphical Abstract
Graphical Abstract
The ASCEND substudy: a summary of results of the observational association between U-TXM and clinical outcomes, and the randomized comparison of aspirin and placebo on U-TXM and clinical outcomes. Observational findings showed positive correlations between U-TXM and SVE-R, and U-TXM and major bleeding. In the randomized comparisons, patients were assigned to aspirin or placebo. Aspirin treatment blocks TXA2 synthesis and therefore reduces U-TXM.9 Aspirin treatment, compared with placebo, lowers TXA2 and reduces SVE-R, and higher U-TXM predicts SVE-R which is consistent with the observational finding. However, aspirin treatment, compared with placebo, lowers U-TXM and increases major bleeding, and U-TXM predicts major bleeding, which is inconsistent with the observational finding.7 Abbreviations: HR, hazard ratio; SVE-R, serious vascular events or revascularizations; TXA2, thromboxane A2; TXB2, thromboxane B2; U-TXM, urine 11-dehydro-thromboxane B2. Square brackets denote concentration |
doi_str_mv | 10.1093/eurheartj/ehae003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2938289162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehae003</oup_id><sourcerecordid>2938289162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-be311d6c9642c1712fb9c4815d51b3c6cc92ff4b66e9dfd30c9f2aee6f18c1e53</originalsourceid><addsrcrecordid>eNqNkLFOwzAQhi0EoqXwACwoIwOhPjtxbTZUUUCqxEIltshxzmpKEgc7qeDtSdXSmemG-_9Pdx8h10DvgSo-xd6vUftuM8W1Rkr5CRlDylisRJKekjEFlcZCyI8RuQhhQymVAsQ5GXGZJOlM8DFZrHzZaP8TdWvv6tx96wYj3RSRL8Nn5GxktC9Kt9XB9JX2EW6x6cJD5F2Fu7UObTkQLsmZ1VXAq8OckNXi6X3-Ei_fnl_nj8vYcM67OEcOUAgz3McMzIDZXJlEQlqkkHMjjFHM2iQXAlVhC06NskwjCgvSAKZ8Qm733Na7rx5Dl9VlMFhVw9muDxlTXDKpQLAhCvuo8S4EjzZrfVkPr2ZAs52-7KgvO-gbOjcHfJ_XWBwbf76GwN0-4Pr2H7xfPJh_zQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2938289162</pqid></control><display><type>article</type><title>Urinary thromboxane and risk of cardiovascular events: role of aspirin</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Eikelboom, John W ; Kruger, Paul C</creator><creatorcontrib>Eikelboom, John W ; Kruger, Paul C</creatorcontrib><description>Graphical Abstract
Graphical Abstract
The ASCEND substudy: a summary of results of the observational association between U-TXM and clinical outcomes, and the randomized comparison of aspirin and placebo on U-TXM and clinical outcomes. Observational findings showed positive correlations between U-TXM and SVE-R, and U-TXM and major bleeding. In the randomized comparisons, patients were assigned to aspirin or placebo. Aspirin treatment blocks TXA2 synthesis and therefore reduces U-TXM.9 Aspirin treatment, compared with placebo, lowers TXA2 and reduces SVE-R, and higher U-TXM predicts SVE-R which is consistent with the observational finding. However, aspirin treatment, compared with placebo, lowers U-TXM and increases major bleeding, and U-TXM predicts major bleeding, which is inconsistent with the observational finding.7 Abbreviations: HR, hazard ratio; SVE-R, serious vascular events or revascularizations; TXA2, thromboxane A2; TXB2, thromboxane B2; U-TXM, urine 11-dehydro-thromboxane B2. Square brackets denote concentration</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehae003</identifier><identifier>PMID: 38445763</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><ispartof>European heart journal, 2024-04, Vol.45 (15), p.1368-1370</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c333t-be311d6c9642c1712fb9c4815d51b3c6cc92ff4b66e9dfd30c9f2aee6f18c1e53</cites><orcidid>0009-0005-2898-2055 ; 0000-0003-4126-1285</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38445763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eikelboom, John W</creatorcontrib><creatorcontrib>Kruger, Paul C</creatorcontrib><title>Urinary thromboxane and risk of cardiovascular events: role of aspirin</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Graphical Abstract
Graphical Abstract
The ASCEND substudy: a summary of results of the observational association between U-TXM and clinical outcomes, and the randomized comparison of aspirin and placebo on U-TXM and clinical outcomes. Observational findings showed positive correlations between U-TXM and SVE-R, and U-TXM and major bleeding. In the randomized comparisons, patients were assigned to aspirin or placebo. Aspirin treatment blocks TXA2 synthesis and therefore reduces U-TXM.9 Aspirin treatment, compared with placebo, lowers TXA2 and reduces SVE-R, and higher U-TXM predicts SVE-R which is consistent with the observational finding. However, aspirin treatment, compared with placebo, lowers U-TXM and increases major bleeding, and U-TXM predicts major bleeding, which is inconsistent with the observational finding.7 Abbreviations: HR, hazard ratio; SVE-R, serious vascular events or revascularizations; TXA2, thromboxane A2; TXB2, thromboxane B2; U-TXM, urine 11-dehydro-thromboxane B2. Square brackets denote concentration</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkLFOwzAQhi0EoqXwACwoIwOhPjtxbTZUUUCqxEIltshxzmpKEgc7qeDtSdXSmemG-_9Pdx8h10DvgSo-xd6vUftuM8W1Rkr5CRlDylisRJKekjEFlcZCyI8RuQhhQymVAsQ5GXGZJOlM8DFZrHzZaP8TdWvv6tx96wYj3RSRL8Nn5GxktC9Kt9XB9JX2EW6x6cJD5F2Fu7UObTkQLsmZ1VXAq8OckNXi6X3-Ei_fnl_nj8vYcM67OEcOUAgz3McMzIDZXJlEQlqkkHMjjFHM2iQXAlVhC06NskwjCgvSAKZ8Qm733Na7rx5Dl9VlMFhVw9muDxlTXDKpQLAhCvuo8S4EjzZrfVkPr2ZAs52-7KgvO-gbOjcHfJ_XWBwbf76GwN0-4Pr2H7xfPJh_zQ</recordid><startdate>20240414</startdate><enddate>20240414</enddate><creator>Eikelboom, John W</creator><creator>Kruger, Paul C</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0005-2898-2055</orcidid><orcidid>https://orcid.org/0000-0003-4126-1285</orcidid></search><sort><creationdate>20240414</creationdate><title>Urinary thromboxane and risk of cardiovascular events: role of aspirin</title><author>Eikelboom, John W ; Kruger, Paul C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-be311d6c9642c1712fb9c4815d51b3c6cc92ff4b66e9dfd30c9f2aee6f18c1e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eikelboom, John W</creatorcontrib><creatorcontrib>Kruger, Paul C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eikelboom, John W</au><au>Kruger, Paul C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary thromboxane and risk of cardiovascular events: role of aspirin</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2024-04-14</date><risdate>2024</risdate><volume>45</volume><issue>15</issue><spage>1368</spage><epage>1370</epage><pages>1368-1370</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Graphical Abstract
Graphical Abstract
The ASCEND substudy: a summary of results of the observational association between U-TXM and clinical outcomes, and the randomized comparison of aspirin and placebo on U-TXM and clinical outcomes. Observational findings showed positive correlations between U-TXM and SVE-R, and U-TXM and major bleeding. In the randomized comparisons, patients were assigned to aspirin or placebo. Aspirin treatment blocks TXA2 synthesis and therefore reduces U-TXM.9 Aspirin treatment, compared with placebo, lowers TXA2 and reduces SVE-R, and higher U-TXM predicts SVE-R which is consistent with the observational finding. However, aspirin treatment, compared with placebo, lowers U-TXM and increases major bleeding, and U-TXM predicts major bleeding, which is inconsistent with the observational finding.7 Abbreviations: HR, hazard ratio; SVE-R, serious vascular events or revascularizations; TXA2, thromboxane A2; TXB2, thromboxane B2; U-TXM, urine 11-dehydro-thromboxane B2. Square brackets denote concentration</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>38445763</pmid><doi>10.1093/eurheartj/ehae003</doi><tpages>3</tpages><orcidid>https://orcid.org/0009-0005-2898-2055</orcidid><orcidid>https://orcid.org/0000-0003-4126-1285</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0195-668X |
ispartof | European heart journal, 2024-04, Vol.45 (15), p.1368-1370 |
issn | 0195-668X 1522-9645 |
language | eng |
recordid | cdi_proquest_miscellaneous_2938289162 |
source | Oxford University Press Journals All Titles (1996-Current) |
title | Urinary thromboxane and risk of cardiovascular events: role of aspirin |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A31%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20thromboxane%20and%20risk%20of%20cardiovascular%20events:%20role%20of%20aspirin&rft.jtitle=European%20heart%20journal&rft.au=Eikelboom,%20John%20W&rft.date=2024-04-14&rft.volume=45&rft.issue=15&rft.spage=1368&rft.epage=1370&rft.pages=1368-1370&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehae003&rft_dat=%3Cproquest_cross%3E2938289162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2938289162&rft_id=info:pmid/38445763&rft_oup_id=10.1093/eurheartj/ehae003&rfr_iscdi=true |